2. Academic Validation
  3. A conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity

A conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity

  • Nat Commun. 2023 Oct 20;14(1):6626. doi: 10.1038/s41467-023-42070-3.
Andras Boeszoermenyi 1,  Léa Bernaleau # 2,  Xudong Chen # 3,  Felix Kartnig 1 4,  Min Xie 3,  Haobo Zhang 2,  Sensen Zhang 3,  Maeva Delacrétaz 2,  Anna Koren 1,  Ann-Katrin Hopp 1,  Vojtech Dvorak 1,  Stefan Kubicek 1,  Daniel Aletaha 4,  Maojun Yang 3 5,  Manuele Rebsamen 6,  Leonhard X Heinz 7,  Giulio Superti-Furga 8 9
Affiliations

Affiliations

  • 1 CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • 2 Department of Immunobiology, University of Lausanne, Epalinges, Switzerland.
  • 3 Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing, China.
  • 4 Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • 5 Cryo-EM Facility Center, Southern University of Science & Technology, Shenzhen, Guangdong, China.
  • 6 Department of Immunobiology, University of Lausanne, Epalinges, Switzerland. manuele.rebsamen@unil.ch.
  • 7 Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. leonhard.heinz@meduniwien.ac.at.
  • 8 CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria. gsuperti@cemm.oeaw.ac.at.
  • 9 Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria. gsuperti@cemm.oeaw.ac.at.
  • # Contributed equally.
PMID: 37863876 DOI: 10.1038/s41467-023-42070-3
Abstract

Dysregulation of pathogen-recognition pathways of the innate immune system is associated with multiple autoimmune disorders. Due to the intricacies of the molecular network involved, the identification of pathway- and disease-specific therapeutics has been challenging. Using a phenotypic assay monitoring the degradation of the immune adapter TASL, we identify feeblin, a chemical entity which inhibits the nucleic acid-sensing TLR7/8 pathway activating IRF5 by disrupting the SLC15A4-TASL adapter module. A high-resolution cryo-EM structure of feeblin with SLC15A4 reveals that the inhibitor binds a lysosomal outward-open conformation incompatible with TASL binding on the cytoplasmic side, leading to degradation of TASL. This mechanism of action exploits a conformational switch and converts a target-binding event into proteostatic regulation of the effector protein TASL, interrupting the TLR7/8-IRF5 signaling pathway and preventing downstream proinflammatory responses. Considering that all components involved have been genetically associated with systemic lupus erythematosus and that feeblin blocks responses in disease-relevant human immune cells from patients, the study represents a proof-of-concept for the development of therapeutics against this disease.

Figures
Products